Carcinoembryonic antigen (CEA), which is synthesized during development in the fetal gut, and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. Anti-CEA is reportedly useful in identifying the origin of various metastatic adenocarcinomas and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+).
Suitable for use in ELISA, Immunoprecipitation, Western Blot and Immunohistochemistry. Other applications not tested.
Immunoprecipitation: 10ul/mg protein lysate. Use Protein A, native and denatured.
Western Blot: 1:200 for 2hrs at RT
Immunohistochemistry (Formalin/paraffin): 1:500-1:1000. Incubate for 30 minutes at RT. No special pretreatment is required for the immunohistochemical staining of formalin/paraffin tissue.
Optimal dilution determined by the researcher.
Recommended Positive Control:
LS174T cells or colon carcinoma
Storage and Stability:
May be stored at 4░C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20░C. Aliquots are stable for 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
| Not determined|
|Human CEA isolated from hepatic metastasis of colon adenocarcinoma. Cellular Localization: Cytoplasmic and lumenal membrane. MW of Antigen: 180kD.|
|Purified by ammonium sulfate precipitation, followed by ion-exchange chromatography and appropriate solid-phase absorption.|
|Supplied as a liquid in PBS, pH 7.4, 0.2% BSA, 0.09% sodium azide.|
|Recognizes human CEA and CEA-like proteins such as non-specific crossreacting antigen (NCA), NCA2, and biliary glycoprotein (BGP1). Has been absorbed with plasma proteins and blood group antigens A and B. Species Crossreactivity: mouse. Weakly reacts with rat. Does not react with canine.|
|Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.|
US Biological application reference: Whited, A. M. et al., (2012) Bionanoscience, DOI: 10.1007/s12668-012-0049-2. 1. Nap, M., et al., Int. J. Biol. Markers 7: 148-153 (1992). 2. Bergeron, A., et al., Cancer Res. 56: 908-915 (1996). 3. Lee, J.S., et al, Acta. Cytologica 40: 631-636 (1996). 4. Nakamura, T., et al., Cancer 77: 1741-1746 (1996). 5.áPrall, F., et al., Journal of Histochemistry and Cytochemistry 44: 35-41 (1996). 6. Sundblad, A., et al., Human Pathology 27: 297-301 (1996). 7. Webb, A., et al., European Journal of Cancer 32A: 63-68 (1996). 8. Moyana, T.N., et al., Cancer 75: 2836-2843 (1995). 9. Parkkila, S., et al., European Journal of Nuclear Medicine 22: 1064-1068 (1995). 10. Rosner, D., et al., Cancer Investigation 13: 573-582 (1995). 11. Tokunaga, N., et al., Diseases of the Colon and Rectum 38: 842-847 (1995).|